ask="32.91"
ask_size="1000"
average_daily_volume="66574"
bid="2.82"
bid_size="500"
book_value="1.19"
change="+0.07"
change_from_200_day_moving_average="-0.88"
change_from_50_day_moving_average="0.03"
change_from_52_week_high="-3.48"
change_From_52_week_low="0.48"
change_in_percent="+2.40%"
close="2.99"
dividend_pay_date="N/A"
dividend_per_share="N/A"
dividend_yield="N/A"
earnings_per_share="-3.90"
ebitda="-15.74M"
eps_estimate_current_year="-3.33"
eps_estimate_next_quarter="-0.82"
eps_estimate_next_year="-2.49"
ex_dividend_date="N/A"
float_shares="5308000"
high="3.00"
high_52_weeks="6.47"
last_trade_date="3/3/2017"
last_trade_price="2.99"
last_trade_size="171"
last_trade_time="4:00pm"
low="2.79"
low_52_weeks="2.51"
market_capitalization="18.83M"
moving_average_200_day="3.87"
moving_average_50_day="2.96"
name="MABVAX THERAPEUTICS"
notes="N/A"
one_year_target_price="18.00"
open="2.90"
pe_ratio="N/A"
peg_ratio="-0.02"
percent_change_from_200_day_moving_average="-22.69%"
percent_change_from_50_day_moving_average="+1.05%"
percent_change_from_52_week_high="-53.82%"
percent_change_from_52_week_low="+18.94%"
previous_close="2.92"
price_eps_estimate_current_year="N/A"
price_eps_Estimate_next_year="N/A"
price_per_book="2.45"
price_per_sales="20.30"
revenue="905615.00"
shares_outstanding="6296000"
short_ratio="7.82"
stock_exchange="NCM"
symbol="MBVX"
volume="33332"
weeks_range_52="2.51 - 6.47"
